Analysts Anticipate Fate Therapeutics, Inc. (NASDAQ:FATE) Will Post Earnings of -$0.43


Equities research analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to announce ($0.43) earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Fate Therapeutics’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.49). Fate Therapeutics posted earnings of ($0.44) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.3%. The company is expected to announce its next quarterly earnings results on Monday, May 10th.

According to Zacks, analysts expect that Fate Therapeutics will report full year earnings of ($1.84) per share for the current fiscal year, with EPS estimates ranging from ($2.27) to ($1.12). For the next financial year, analysts expect that the company will post earnings of ($2.22) per share, with EPS estimates ranging from ($2.82) to ($1.46). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Wednesday, February 24th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.23). Fate Therapeutics had a negative net margin of 810.13% and a negative return on equity of 35.51%.

Several research firms recently commented on FATE. Stifel Nicolaus upped their target price on Fate Therapeutics from $79.00 to $118.00 and gave the company a “buy” rating in a research note on Monday, December 21st. SVB Leerink increased their price objective on shares of Fate Therapeutics from $58.00 to $121.00 and gave the stock an “outperform” rating in a report on Thursday, March 18th. Citigroup cut shares of Fate Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, February 11th. They noted that the move was a valuation call. Bank of America started coverage on shares of Fate Therapeutics in a research report on Friday, February 26th. They set a “buy” rating and a $115.00 price target for the company. Finally, Mizuho lifted their price target on shares of Fate Therapeutics from $88.00 to $109.00 and gave the company a “buy” rating in a report on Wednesday, March 3rd. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $108.29.

(Ad)

Newly-minted stock market millionaires will be making a tour de force in 2021 by being early on select green energy stocks. This $0.20 stock just seized control of an ultra-rare clean energy metal America needs to lead the green energy revolution.

In other Fate Therapeutics news, Director Redmile Group, Llc purchased 327,485 shares of the business’s stock in a transaction that occurred on Friday, January 8th. The shares were acquired at an average price of $85.50 per share, for a total transaction of $27,999,967.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO J Scott Wolchko sold 60,820 shares of the stock in a transaction dated Friday, January 8th. The shares were sold at an average price of $117.10, for a total value of $7,122,022.00. Following the completion of the transaction, the chief executive officer now directly owns 393,065 shares of the company’s stock, valued at approximately $46,027,911.50. The disclosure for this sale can be found here. Insiders have sold a total of 251,651 shares of company stock worth $28,251,869 in the last ninety days. 21.41% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. Perigon Wealth Management LLC acquired a new stake in Fate Therapeutics in the fourth quarter valued at $28,000. AdvisorNet Financial Inc raised its stake in shares of Fate Therapeutics by 83.9% in the 4th quarter. AdvisorNet Financial Inc now owns 570 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 260 shares in the last quarter. First Mercantile Trust Co. acquired a new position in Fate Therapeutics in the fourth quarter worth about $81,000. Lazard Asset Management LLC bought a new stake in Fate Therapeutics in the fourth quarter valued at about $143,000. Finally, Princeton Global Asset Management LLC bought a new stake in Fate Therapeutics in the fourth quarter valued at about $182,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Shares of Fate Therapeutics stock opened at $82.45 on Thursday. Fate Therapeutics has a fifty-two week low of $19.81 and a fifty-two week high of $121.16. The business’s fifty day moving average is $91.83 and its two-hundred day moving average is $75.38. The firm has a market cap of $7.73 billion, a PE ratio of -44.81 and a beta of 1.88.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors.

See Also: What are high-yield dividend stocks?

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

12 Marijuana Stocks to Buy Now

There are now more than 50 publicly-traded companies operating in the cannabis industry. Most of these companies aren’t directly growing and selling marijuana themselves, but they do stand to benefit greatly as more states legalize the sale and possession of marijuana. Some of these marijuana stocks are media companies. Others are privately studying the medical uses of marijuana. Yet others are providing tools and software for marijuana growers. As more cannabis companies file IPOs and enter the stock market, it will become increasingly difficult for investors to identify which marijuana stocks will truly benefit from the cannabis boom.

Our subscribers have begun digging through these companies, checking out their financials, business models and long-term growth prospects. They know that some “marijuana stocks” are just empty shell companies that deserve to be penny stocks, but they also recognize there are some legitimate and growing companies that truly stand to benefit from the green rush. As a group, they have added 10 different cannabis stocks to their watchlists and are actively investing in them. More than 1,400 MarketBeat subscribers are now following our top-trending cannabis company.

This slide show lists the 12 pot stocks that MarketBeat subscribers are have added to their watchlists and are actively monitoring.

View the “12 Marijuana Stocks to Buy Now”.



Read More:Analysts Anticipate Fate Therapeutics, Inc. (NASDAQ:FATE) Will Post Earnings of -$0.43

Leave a Reply

Your email address will not be published. Required fields are marked *